Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Therapeutics Announces Lead Candidate Equipment Supplied In Europe
14 equipment items found
Manufactured by:ZIND Verfahrenstechnik based inMainz, GERMANY
At pilot stage, the primary membrane candidate has been chosen, as process parameters. Typically at this stage, the production method is being verified and production materials produced for toxicology or pre-clinical trials and predictable scalability is imperative. In order to facilitate the manufacturing life cycle of a successful therapeutic candidate, cGMP manufacturing needs to begin at ...
Manufactured by:VECT-HORUS based inMARSEILLE, FRANCE
Vect-Horus has developed its “VECTrans®” breakthrough technology platform with the objective of making the ‘undruggable’ druggable by overcoming challenges of the BBB, and more generally biological barriers. VECTrans® is based on the specific design and optimization of ‘molecular vectors’ that, once conjugated to a payload, enable its delivery to target ...
by:Redbiotec AG based inSchlieren, SWITZERLAND
Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine ...
Manufactured by:Mimetas B.V. based inLeiden, NETHERLANDS
Profiling and screening of your compounds with a high throughput barrier integrity assay on our established Caco-2 intestinal model. OrganoServices are available for multiple assays to allow compound profiling and/or screening in human-relevant, complex 3D tissue models. When developing new drugs, it is critical to understand the permeability, absorption, and transport mechanisms in relevant ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
GPEx cell line development technology is a proven technology that generates high-performance, highly stable, production cell lines. Virtually any cDNA (mAb and multigenic applications) can be inserted into cells. To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic ...
Manufactured by:Newcells Biotech Limited based inNewcastle Upon Tyne, UNITED KINGDOM
Human lung fibroblast model to test the efficacy of anti-fibrotic agents in vitro. Newcells human primary lung fibroblast model is the basis of our FMT assay to evaluate anti-fibrotic therapies in vitro at high throughput. The assay replicates extracellular matrix deposition (ECM) observed in vivo when lung fibroblast injury leads to activation and proliferation. Following injury, pulmonary ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
Disturbances in calcium signaling are associated with many neurodegenerative diseases and cardiomyopathies. Fluorescence-based assays with iPSC-derived cardiac and neuronal models can be used to monitor short and long-term drug-induced changes on calcium transients. Our scientists develop the most optimal calcium transient assay for each project and can scale it up for high-throughput screening, ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within all humans, representing approximately 1-5% of the circulating population. As part of the immune system's innate response, their natural properties make ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
Astrocytes are essential players in neurodegenerative disease progression providing a valuable tool for drug discovery and disease modeling. Human iPSC-derived astrocytes generated with our standardized process express key identity markers and support co-culture with human iPSC-derived neurons. Our team can manufacture astrocytes at scale from the iPSC that best fits your project or work with ...
by:Carbiotix AB based inLund, SWEDEN
Carbiotix believes that activity within the gut microbiome is more important than the presence of specific bacteria species. As such, the company focuses on engineering microbiome modulators (proprietary second-generation soluble fibres, isolated bacterial strains, and novel delivery mechanisms) to restore and optimize gut microbiome metabolic processes, and thereby obtain the desired effect ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
Human-induced pluripotent stem cell (iPSC) derived atrial cardiomyocytes are a powerful tool to improve in vitro testing of new treatments for atrial arrhythmias. Our team can manufacture atrial cardiomyocytes at the scale needed from the iPSC that best fits your project, ensuring high purity and consistency between batches. Custom assays can be developed based on this model to support your large ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies. The video below provides more ...
by:Pure Biologics SA based inWroclaw, POLAND
Colorectal cancer (CRC) is the second-most common cancer diagnosed in women and third-most in men. Based upon five-year survival rates, chances of becoming cured remain to be approximately 65%. Therapies targeting immunological checkpoints, or more specifically their inhibition, promise effective treatment options for patients with metastatic forms of this disease. In the PB001 project, Pure ...